201 related articles for article (PubMed ID: 23443110)
21. lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axis.
Hu M; Zhang Q; Tian XH; Wang JL; Niu YX; Li G
Mol Carcinog; 2019 Dec; 58(12):2207-2217. PubMed ID: 31544294
[TBL] [Abstract][Full Text] [Related]
22. T-box transcription factor TBX1, targeted by microRNA-6727-5p, inhibits cell growth and enhances cisplatin chemosensitivity of cervical cancer cells through AKT and MAPK pathways.
Liu H; Song M; Sun X; Zhang X; Miao H; Wang Y
Bioengineered; 2021 Dec; 12(1):565-577. PubMed ID: 33557670
[TBL] [Abstract][Full Text] [Related]
23. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin.
Feng Y; Zou W; Hu C; Li G; Zhou S; He Y; Ma F; Deng C; Sun L
Arch Biochem Biophys; 2017 Jun; 623-624():20-30. PubMed ID: 28495512
[TBL] [Abstract][Full Text] [Related]
24. MiR-181a Promotes Apoptosis and Reduces Cisplatin Resistance by Inhibiting Osteopontin in Cervical Cancer Cells.
Xu X; Jiang X; Chen L; Zhao Y; Huang Z; Zhou H; Shi M
Cancer Biother Radiopharm; 2019 Nov; 34(9):559-565. PubMed ID: 31436472
[No Abstract] [Full Text] [Related]
25. MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes.
Yang F; Guo L; Cao Y; Li S; Li J; Liu M
Med Sci Monit; 2018 Sep; 24():6506-6516. PubMed ID: 30219819
[TBL] [Abstract][Full Text] [Related]
26. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy.
Zou Z; Wu L; Ding H; Wang Y; Zhang Y; Chen X; Chen X; Zhang CY; Zhang Q; Zen K
J Biol Chem; 2012 Feb; 287(6):4148-56. PubMed ID: 22157765
[TBL] [Abstract][Full Text] [Related]
28. miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells.
Song J; Li Y
Cancer Sci; 2017 Jan; 108(1):23-31. PubMed ID: 27743413
[TBL] [Abstract][Full Text] [Related]
29. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.
Wu H; Xiao Z; Zhang H; Wang K; Liu W; Hao Q
Anticancer Drugs; 2014 Aug; 25(7):799-809. PubMed ID: 24686007
[TBL] [Abstract][Full Text] [Related]
30. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.
Shi L; Xi J; Xu X; Peng B; Zhang B
Biomed Pharmacother; 2019 Jan; 109():902-909. PubMed ID: 30551544
[TBL] [Abstract][Full Text] [Related]
31. MiR-23b controls ALDH1A1 expression in cervical cancer stem cells.
Wang W; Li Y; Liu N; Gao Y; Li L
BMC Cancer; 2017 Apr; 17(1):292. PubMed ID: 28449663
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
Cheng C; Qin Y; Zhi Q; Wang J; Qin C
Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
[TBL] [Abstract][Full Text] [Related]
33. DANCR-mediated microRNA-665 regulates proliferation and metastasis of cervical cancer through the ERK/SMAD pathway.
Cao L; Jin H; Zheng Y; Mao Y; Fu Z; Li X; Dong L
Cancer Sci; 2019 Mar; 110(3):913-925. PubMed ID: 30582654
[TBL] [Abstract][Full Text] [Related]
34. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
35. Silencing CDR1as enhances the sensitivity of breast cancer cells to drug resistance by acting as a miR-7 sponge to down-regulate REGγ.
Yang W; Yang X; Wang X; Gu J; Zhou D; Wang Y; Yin B; Guo J; Zhou M
J Cell Mol Med; 2019 Aug; 23(8):4921-4932. PubMed ID: 31245927
[TBL] [Abstract][Full Text] [Related]
36. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
37. PBK promotes aggressive phenotypes of cervical cancer through ERK/c-Myc signaling pathway.
Ma H; Han F; Yan X; Qi G; Li Y; Li R; Yan S; Yuan C; Song K; Kong B
J Cell Physiol; 2021 Apr; 236(4):2767-2781. PubMed ID: 33184870
[TBL] [Abstract][Full Text] [Related]
38. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.
Li R; Liu GZ; Luo SY; Chen R; Zhang JX
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4533-41. PubMed ID: 26698249
[TBL] [Abstract][Full Text] [Related]
39. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
40. Nuclear factor-κB-dependent microRNA-130a upregulation promotes cervical cancer cell growth by targeting phosphatase and tensin homolog.
Feng Y; Zhou S; Li G; Hu C; Zou W; Zhang H; Sun L
Arch Biochem Biophys; 2016 May; 598():57-65. PubMed ID: 27040383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
